Groton, CT – According to filings with the U.S. Securities and Exchange Commission, Astrocyte Pharmaceuticals is raising $8,655,148.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Korinek played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Inc. is a small drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte Pharmaceuticals is pursuing an innovative neuroprotective strategy to protect and repair neurons that are damaged by selectively stimulating astrocytes. This enables selective activation of their caretaker processes including the removal of harmful extracellular molecules and the restoration of ion homeostasis. The company is investigating and advancing small molecule pharmaceutical medicines that will provide neuroprotection to a range of brain injury patients.

To learn more about Astrocyte Pharmaceuticals, visit http://www.astrocytepharma.com/

Contact:
William Korinek, Chief Executive Officer
617-444-8765
https://www.linkedin.com/in/william-korinek-42415a1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved